173 related articles for article (PubMed ID: 31612917)
1. Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab.
Sudo K; Kato K; Matsuzaki J; Takizawa S; Aoki Y; Shoji H; Iwasa S; Honma Y; Takashima A; Sakamoto H; Naka T; Sekine S; Boku N; Ochiya T
Jpn J Clin Oncol; 2020 Feb; 50(2):114-121. PubMed ID: 31612917
[TBL] [Abstract][Full Text] [Related]
2. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.
Niwa Y; Yamada S; Sonohara F; Kurimoto K; Hayashi M; Tashiro M; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
J Transl Med; 2019 Jan; 17(1):1. PubMed ID: 30602370
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling.
Sudo K; Kato K; Matsuzaki J; Boku N; Abe S; Saito Y; Daiko H; Takizawa S; Aoki Y; Sakamoto H; Niida S; Takeshita F; Fukuda T; Ochiya T
JAMA Netw Open; 2019 May; 2(5):e194573. PubMed ID: 31125107
[TBL] [Abstract][Full Text] [Related]
5. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus.
Slotta-Huspenina J; Drecoll E; Feith M; Habermehl D; Combs S; Weichert W; Bettstetter M; Becker K; Langer R
J Transl Med; 2018 Apr; 16(1):109. PubMed ID: 29695253
[TBL] [Abstract][Full Text] [Related]
7. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
8. A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma.
Zhou X; Wen W; Zhu J; Huang Z; Zhang L; Zhang H; Qi LW; Shan X; Wang T; Cheng W; Zhu D; Yin Y; Chen Y; Zhu W; Shu Y; Liu P
Oncotarget; 2017 May; 8(21):34468-34480. PubMed ID: 28380431
[TBL] [Abstract][Full Text] [Related]
9. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma.
Xu H; Yang Y; Zhao H; Yang X; Luo Y; Ren Y; Liu W; Li N
Tumour Biol; 2016 Jan; 37(1):447-53. PubMed ID: 26224475
[TBL] [Abstract][Full Text] [Related]
10. Identification of microRNAs as novel biomarkers for esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas (TCGA) and bioinformatics.
Li CY; Zhang WW; Xiang JL; Wang XH; Li J; Wang JL
Chin Med J (Engl); 2019 Sep; 132(18):2213-2222. PubMed ID: 31490264
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
Kudo T; Hamamoto Y; Kato K; Ura T; Kojima T; Tsushima T; Hironaka S; Hara H; Satoh T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Doki Y; Kitagawa Y
Lancet Oncol; 2017 May; 18(5):631-639. PubMed ID: 28314688
[TBL] [Abstract][Full Text] [Related]
12. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
13. Serum expression of selected miRNAs in patients with laryngeal squamous cell carcinoma (LSCC).
Lucas Grzelczyk W; Szemraj J; Kwiatkowska S; Józefowicz-Korczyńska M
Diagn Pathol; 2019 May; 14(1):49. PubMed ID: 31138255
[TBL] [Abstract][Full Text] [Related]
14. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
15. Expression of circulating microRNA-20a and let-7a in esophageal squamous cell carcinoma.
He FC; Meng WW; Qu YH; Zhou MX; He J; Lv P; Ming L
World J Gastroenterol; 2015 Apr; 21(15):4660-5. PubMed ID: 25914476
[TBL] [Abstract][Full Text] [Related]
16. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Meindl-Beinker NM; Betge J; Gutting T; Burgermeister E; Belle S; Zhan T; Schulte N; Maenz M; Ebert MP; Haertel N
BMC Cancer; 2019 Mar; 19(1):231. PubMed ID: 30871493
[TBL] [Abstract][Full Text] [Related]
17. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K
J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789
[TBL] [Abstract][Full Text] [Related]
18. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Wang WT; Guo CQ; Cui GH; Zhao S
World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
[TBL] [Abstract][Full Text] [Related]
19. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profiling analysis in serum for nasopharyngeal carcinoma diagnosis.
Zou X; Zhu D; Zhang H; Zhang S; Zhou X; He X; Zhu J; Zhu W
Gene; 2020 Feb; 727():144243. PubMed ID: 31743768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
